AAPL347.86-0.37 (-0.10%) ▼|ABBV285.28+0.09 (+0.03%) ▲|ABT102.99+0.48 (+0.47%) ▲|ACN247.30-11.44 (-4.42%) ▼|ADBE264.70-5.85 (-2.16%) ▼|AMAT382.35+6.77 (+1.80%) ▲|AMD518.40+10.47 (+2.06%) ▲|AMGN442.41-4.87 (-1.09%) ▼|AMT189.80+8.23 (+4.53%) ▲|AMZN249.56-0.82 (-0.33%) ▼|AVGO325.34+2.10 (+0.65%) ▲|AXP313.32-11.85 (-3.64%) ▼|BA186.84-0.72 (-0.38%) ▼|BAC50.79-0.29 (-0.57%) ▼|BKNG156.79-4.31 (-2.68%) ▼|BLK1,121.03-16.26 (-1.43%) ▼|BMY61.73-1.27 (-2.02%) ▼|BNY145.21-0.12 (-0.08%) ▼|BRK-B544.61-2.36 (-0.43%) ▼|C121.01-1.50 (-1.22%) ▼|CAT689.05-15.00 (-2.13%) ▼|CL94.15-3.24 (-3.33%) ▼|CMCSA22.71-0.14 (-0.59%) ▼|COF201.07-2.36 (-1.16%) ▼|COP152.43+6.80 (+4.67%) ▲|COST1,007.27-10.94 (-1.07%) ▼|CRM245.43-4.86 (-1.94%) ▼|CSCO106.52+1.63 (+1.55%) ▲|CVS93.67-0.81 (-0.86%) ▼|CVX232.96+6.28 (+2.77%) ▲|DE645.04+1.42 (+0.22%) ▲|DHR225.92-3.84 (-1.67%) ▼|DIS112.79-0.34 (-0.30%) ▼|DUK124.61-0.79 (-0.63%) ▼|EMR161.41+1.12 (+0.70%) ▲|FDX298.81-5.11 (-1.68%) ▼|GD348.42-2.38 (-0.68%) ▼|GE286.43-7.11 (-2.42%) ▼|GEV825.86-1.57 (-0.19%) ▼|GILD156.94-0.25 (-0.16%) ▼|GM75.54-1.67 (-2.16%) ▼|GOOG320.45-0.31 (-0.10%) ▼|GOOGL323.61-0.62 (-0.19%) ▼|GS885.04-6.26 (-0.70%) ▼|HD319.01-8.72 (-2.66%) ▼|HON219.15+0.84 (+0.38%) ▲|IBM252.62+0.51 (+0.20%) ▲|INTC87.06+1.57 (+1.84%) ▲|INTU345.79-9.11 (-2.57%) ▼|ISRG456.87+13.02 (+2.93%) ▲|JNJ262.87-4.75 (-1.77%) ▼|JPM332.01-4.53 (-1.35%) ▼|KO93.28-2.07 (-2.17%) ▼|LIN510.41+0.05 (+0.01%) ▲|LLY1,282.45-24.24 (-1.86%) ▼|LMT597.36+7.45 (+1.26%) ▲|LOW198.63-5.75 (-2.81%) ▼|LRCX233.12+2.97 (+1.29%) ▲|MA622.00-11.22 (-1.77%) ▼|MCD247.86-4.77 (-1.89%) ▼|MDLZ63.63-1.56 (-2.39%) ▼|MDT96.12-0.47 (-0.49%) ▼|META645.93-2.92 (-0.45%) ▼|MMM174.02-1.54 (-0.88%) ▼|MO74.96-1.11 (-1.46%) ▼|MRK144.97-2.27 (-1.54%) ▼|MS181.42-2.55 (-1.39%) ▼|MSFT524.63+3.55 (+0.68%) ▲|MU885.55+29.06 (+3.39%) ▲|NEE81.90-0.01 (-0.01%) ▼|NFLX67.02-0.04 (-0.05%) ▼|NKE37.68-0.65 (-1.68%) ▼|NOW156.83-0.17 (-0.11%) ▼|NVDA212.30+0.09 (+0.04%) ▲|ORCL127.44+1.90 (+1.51%) ▲|PEP135.08-3.75 (-2.70%) ▼|PFE30.10-0.33 (-1.07%) ▼|PG161.17-3.34 (-2.03%) ▼|PLTR195.88-0.32 (-0.16%) ▼|PM200.57-1.17 (-0.58%) ▼|QCOM174.86+2.03 (+1.17%) ▲|RTX191.21-3.50 (-1.80%) ▼|SBUX101.04-0.87 (-0.85%) ▼|SCHW90.24-1.20 (-1.31%) ▼|SO93.12-0.70 (-0.75%) ▼|SPG211.38-0.67 (-0.31%) ▼|T21.47-1.28 (-5.61%) ▼|TMO667.19-9.36 (-1.38%) ▼|TMUS150.15-8.64 (-5.44%) ▼|TSLA372.04-2.54 (-0.68%) ▼|TXN285.04+5.54 (+1.98%) ▲|UBER67.84-1.23 (-1.78%) ▼|UNH423.36-1.63 (-0.38%) ▼|UNP293.49-4.60 (-1.54%) ▼|UPS100.67-0.86 (-0.84%) ▼|USB59.61-0.42 (-0.69%) ▼|V408.98-5.36 (-1.29%) ▼|VZ44.57-0.64 (-1.40%) ▼|WFC82.45-0.56 (-0.67%) ▼|WMT119.96-1.16 (-0.96%) ▼|XOM183.02+4.79 (+2.69%) ▲|AAPL347.86-0.37 (-0.10%) ▼|ABBV285.28+0.09 (+0.03%) ▲|ABT102.99+0.48 (+0.47%) ▲|ACN247.30-11.44 (-4.42%) ▼|ADBE264.70-5.85 (-2.16%) ▼|AMAT382.35+6.77 (+1.80%) ▲|AMD518.40+10.47 (+2.06%) ▲|AMGN442.41-4.87 (-1.09%) ▼|AMT189.80+8.23 (+4.53%) ▲|AMZN249.56-0.82 (-0.33%) ▼|AVGO325.34+2.10 (+0.65%) ▲|AXP313.32-11.85 (-3.64%) ▼|BA186.84-0.72 (-0.38%) ▼|BAC50.79-0.29 (-0.57%) ▼|BKNG156.79-4.31 (-2.68%) ▼|BLK1,121.03-16.26 (-1.43%) ▼|BMY61.73-1.27 (-2.02%) ▼|BNY145.21-0.12 (-0.08%) ▼|BRK-B544.61-2.36 (-0.43%) ▼|C121.01-1.50 (-1.22%) ▼|CAT689.05-15.00 (-2.13%) ▼|CL94.15-3.24 (-3.33%) ▼|CMCSA22.71-0.14 (-0.59%) ▼|COF201.07-2.36 (-1.16%) ▼|COP152.43+6.80 (+4.67%) ▲|COST1,007.27-10.94 (-1.07%) ▼|CRM245.43-4.86 (-1.94%) ▼|CSCO106.52+1.63 (+1.55%) ▲|CVS93.67-0.81 (-0.86%) ▼|CVX232.96+6.28 (+2.77%) ▲|DE645.04+1.42 (+0.22%) ▲|DHR225.92-3.84 (-1.67%) ▼|DIS112.79-0.34 (-0.30%) ▼|DUK124.61-0.79 (-0.63%) ▼|EMR161.41+1.12 (+0.70%) ▲|FDX298.81-5.11 (-1.68%) ▼|GD348.42-2.38 (-0.68%) ▼|GE286.43-7.11 (-2.42%) ▼|GEV825.86-1.57 (-0.19%) ▼|GILD156.94-0.25 (-0.16%) ▼|GM75.54-1.67 (-2.16%) ▼|GOOG320.45-0.31 (-0.10%) ▼|GOOGL323.61-0.62 (-0.19%) ▼|GS885.04-6.26 (-0.70%) ▼|HD319.01-8.72 (-2.66%) ▼|HON219.15+0.84 (+0.38%) ▲|IBM252.62+0.51 (+0.20%) ▲|INTC87.06+1.57 (+1.84%) ▲|INTU345.79-9.11 (-2.57%) ▼|ISRG456.87+13.02 (+2.93%) ▲|JNJ262.87-4.75 (-1.77%) ▼|JPM332.01-4.53 (-1.35%) ▼|KO93.28-2.07 (-2.17%) ▼|LIN510.41+0.05 (+0.01%) ▲|LLY1,282.45-24.24 (-1.86%) ▼|LMT597.36+7.45 (+1.26%) ▲|LOW198.63-5.75 (-2.81%) ▼|LRCX233.12+2.97 (+1.29%) ▲|MA622.00-11.22 (-1.77%) ▼|MCD247.86-4.77 (-1.89%) ▼|MDLZ63.63-1.56 (-2.39%) ▼|MDT96.12-0.47 (-0.49%) ▼|META645.93-2.92 (-0.45%) ▼|MMM174.02-1.54 (-0.88%) ▼|MO74.96-1.11 (-1.46%) ▼|MRK144.97-2.27 (-1.54%) ▼|MS181.42-2.55 (-1.39%) ▼|MSFT524.63+3.55 (+0.68%) ▲|MU885.55+29.06 (+3.39%) ▲|NEE81.90-0.01 (-0.01%) ▼|NFLX67.02-0.04 (-0.05%) ▼|NKE37.68-0.65 (-1.68%) ▼|NOW156.83-0.17 (-0.11%) ▼|NVDA212.30+0.09 (+0.04%) ▲|ORCL127.44+1.90 (+1.51%) ▲|PEP135.08-3.75 (-2.70%) ▼|PFE30.10-0.33 (-1.07%) ▼|PG161.17-3.34 (-2.03%) ▼|PLTR195.88-0.32 (-0.16%) ▼|PM200.57-1.17 (-0.58%) ▼|QCOM174.86+2.03 (+1.17%) ▲|RTX191.21-3.50 (-1.80%) ▼|SBUX101.04-0.87 (-0.85%) ▼|SCHW90.24-1.20 (-1.31%) ▼|SO93.12-0.70 (-0.75%) ▼|SPG211.38-0.67 (-0.31%) ▼|T21.47-1.28 (-5.61%) ▼|TMO667.19-9.36 (-1.38%) ▼|TMUS150.15-8.64 (-5.44%) ▼|TSLA372.04-2.54 (-0.68%) ▼|TXN285.04+5.54 (+1.98%) ▲|UBER67.84-1.23 (-1.78%) ▼|UNH423.36-1.63 (-0.38%) ▼|UNP293.49-4.60 (-1.54%) ▼|UPS100.67-0.86 (-0.84%) ▼|USB59.61-0.42 (-0.69%) ▼|V408.98-5.36 (-1.29%) ▼|VZ44.57-0.64 (-1.40%) ▼|WFC82.45-0.56 (-0.67%) ▼|WMT119.96-1.16 (-0.96%) ▼|XOM183.02+4.79 (+2.69%) ▲|
13.2 C
New York
Friday, October 23, 2026

Tag: candidates

Booking Health Unveils New Study: Role of Immunotherapy in Extending Life Expectancy for Stage4 Cervical Cancer Patients

Langenfeld, Germany, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Booking Health, a global leader in medical treatment coordination, today unveiled a new study titled Role of Immunotherapy in Extending Life Expectancy for Stage 4 Cervical Cancer Patients. The report outlines how cutting-edge immunotherapy is reshaping care for women with advanced cervical cancer, offering new pathways to longer survival and improved quality of life, particularly in cases resistant to standard treatments.

REPEAT — Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion...

WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced its top-line revenue forecast for its specialty care pipeline, projecting nearly $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $18 billion and $22 billion. This forecast reflects the company’s unique, faster, and cost-efficient drug development model which has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come.

REPEAT – Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders

WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today released a letter to stockholders.

Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

COPENHAGEN, Denmark, August 11, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its second quarter 2025 financial results on Thursday August 14, 2025, before opening of the Nasdaq CM.

Akeso Announces First Patient Dosed in Phase III Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy

HONG KONG, Aug. 10, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its multicenter,...

Is Plastic Surgery Safe with Medical Conditions? Dr. Thomas Pane Explains in New Video

PALM BEACH GARDENS, Fla., Aug. 9, 2025 /PRNewswire/ -- For patients considering plastic surgery with underlying medical conditions, Dr. Thomas A. Pane, MD, offers...

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

– Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant –

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

JERUSALEM, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended June 30, 2025.

Hyperion Defi to Report Second Quarter 2025 Results on Wednesday, August 13, 2025

Company to host an investor conference call and webcast at 4:30 pm ET
Company to host an investor conference call and webcast at 4:30 pm ET

CPABC: 267 B.C. CPA candidates succeed in national exam

VANCOUVER, British Columbia, Aug. 08, 2025 (GLOBE NEWSWIRE) -- The Chartered Professional Accountants of British Columbia (CPABC) and the CPA Western School of Business (CPAWSB) congratulate the 267 B.C. CPA candidates who passed the multi-day national Common Final Examination (CFE) written in May 2025. The exam was administered by CPAWSB.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCandidates